CKD Clinical Trial - Thyroid Dysfunction & Dyslipidemia in Patients With

Status Not yet recruiting

Clinical Trial Summary

Early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in CKD patients may be highly beneficial to slow progression of CKD. The study will be conducted to investigate thyroid function and lipid profile in patients with chronic kidney disease.

Clinical Trial Description

Chronic kidney disease[CKD] is becoming a serious health problem.The number of people with impaired renal function is rapidly rising, especially in industrialized countries. It is increasing rapidly worldwide at an annual growth rate of 8%. Chronic kidney disease [CKD] is defined as kidney disease that has been present for months to years. Chronic kidney disease [CKD] is a complex disease impacting more than twenty million individuals. Progression of CKD is associated with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia and metabolic bone disease .CKD patients should be assessed for the presence of these complications and receive optimal treatment to reduce their morbidity and mortality .

CKD affects thyroid function in many ways, including low thyroid circulating hormone levels, altered peripheral hormone metabolism, insufficient binding to carrier proteins, reduced tissue thyroid hormone content and altered iodine storage in the thyroid gland.Thus,inCKD,thyroid hormone metabolism is impaired. . Hypothyroidism in patients with renal failure causes many metabolic and clinical problems, and both these diseases can mutually exacerbate their disturbances.. Chronic kidney disease has been known to affect thyroid hormones metabolism .Low serum level of T3 and T4 are most remarkable laboratorial finding. A high incidence of goiter and nodules on thyroid ultrasonography has been reported in patients with end stage renal failure[ESRF]. CKD is often associated with dyslipidemia. Several factors contribute to these changes. Patient with CKD have a reduction in the activity of lipoprotein lipase and hepatic triglyceride lipase. This interferes with uptake of triglyceride rich Apo lipoprotein B containing lipoprotein by the liver and in peripheral tissue, yielding increased circulation of these atherogenic lipoproteins. Early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in CKD patients may be highly beneficial to slow progression of CKD. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03277911
Study type	Observational
Source	Assiut University
Contact
Status	Not yet recruiting
Phase	N/A
Start date	September 10, 2017
Completion date	August 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04008810` - Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
Completed	`NCT05144971` - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Active, not recruiting	`NCT05356325` - FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.
Not yet recruiting	`NCT04491669` - Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients
Completed	`NCT04709120` - Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
Terminated	`NCT03277183` - Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin	Phase 4
Enrolling by invitation	`NCT04491227` - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Recruiting	`NCT06279429` - Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia	N/A
Recruiting	`NCT03501745` - Smart-CKD/BP Study	N/A
Recruiting	`NCT04708743` - The Tongue Features Associated With Chronic Kidney Disease
Recruiting	`NCT06416761` - Genetics in the Progression of Nephropathies
Completed	`NCT04119570` - CKD Report Card Pilot Trial	N/A
Completed	`NCT06374043` - Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.	Phase 4
Not yet recruiting	`NCT06094920` - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	Phase 4
Recruiting	`NCT04819217` - Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease	N/A
Completed	`NCT05970094` - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5	N/A
Withdrawn	`NCT04782297` - Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
Recruiting	`NCT05784389` - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5	N/A
Recruiting	`NCT04630132` - Renal Ageing-sarcopenia Network
Not yet recruiting	`NCT06143098` - Some Hematological Profile in Children With Chronic Kidney Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms